SAN DIEGO, July 19, 2018 /PRNewswire/ -- NuVasive, Inc.
(NASDAQ: NUVA), the leader in spine technology innovation, focused
on transforming spine surgery with minimally disruptive,
procedurally-integrated solutions, today announced the U.S. launch
of MAGEC X, a new procedural solution within the MAGEC product
family that addresses Early Onset Scoliosis (EOS).
MAGEC X features updates across all rod diameters in the
portfolio, including 5.0mm diameter rods for patients, delivering a
68 percent performance increase over the previous generation in
titanium rod fatigue testing. When paired with the NuVasive
Reline® Small Stature system, the first pediatric deformity
fixation solution to integrate both 4.5mm and 5.0mm rods in a
low-profile tulip, MAGEC X provides increased construct strength
without sacrificing the optimal profile for EOS patients.
"NuVasive's MAGEC X 5.0mm solution is unique because it allows
you to upsize your rod with low-profile screws, giving you the
flexibility at the time of surgery to use a larger rod without
having to change your screws – that's really key," said Dr.
Peter Sturm, Alvin H. Crawford Chair
of Spine Surgery, Cincinnati Children's Hospital Medical Center.
"Further, the upgrade of the internal components in MAGEC X rods
gives me even more confidence in the performance of a system that
has radically changed how we treat this challenging patient
population."
The development of MAGEC X is also distinguished by a number of
internal rod mechanism advancements, most notably a reinforced
locking pin and a robust actuator seal designed to further contain
and reduce the release of titanium wear debris. Additionally, it
includes an anti-jam feature to simplify intraoperative and
postoperative rod lengthening. Key aesthetic improvements, such as
laser-marked sagittal bending lines, help to enhance surgeon
workflow efficiency and ease of use.
"More than 100,000 children are diagnosed with scoliosis each
year in the United States; the
launch of MAGEC X exemplifies our continued dedication to the
advancement of EOS treatment and support of the pediatric surgeon
community," said Matt Link,
executive vice president, strategy, technology and corporate
development for NuVasive. "MAGEC X represents the culmination of
over a decade of clinical experience and innovation, resulting in a
stronger and smarter MAGEC implant design."
This full commercial launch of MAGEC X follows the Company's
preview announcement, which occurred at the POSNA Annual Meeting in
May in Austin, Texas.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology
innovation, focused on transforming spine surgery and beyond with
minimally disruptive, procedurally-integrated solutions designed to
deliver reproducible and clinically-proven surgical outcomes. The
Company's portfolio includes access instruments, implantable
hardware, biologics, software systems for surgical planning,
navigation and imaging solutions, magnetically adjustable implant
systems for spine and orthopedics, and intraoperative monitoring
service offerings. With over $1
billion in revenues, NuVasive has an approximate 2,400
person workforce in more than 40 countries serving surgeons,
hospitals and patients. For more information, please visit
www.nuvasive.com.
Forward-Looking Statements
NuVasive cautions you that statements included in this news release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties which contribute
to the uncertain nature of these statements include, among others,
risks associated with acceptance of the Company's surgical products
and procedures by spine surgeons, development and acceptance of new
products or product enhancements, clinical and statistical
verification of the benefits achieved via the use of NuVasive's
products (including the iGA® platform), the Company's ability to
effectually manage inventory as it continues to release new
products, its ability to recruit and retain management and key
personnel, and the other risks and uncertainties described in
NuVasive's news releases and periodic filings with the Securities
and Exchange Commission. NuVasive's public filings with the
Securities and Exchange Commission are available at www.sec.gov.
NuVasive assumes no obligation to update any forward-looking
statement to reflect events or circumstances arising after the date
on which it was made.
View original content with
multimedia:http://www.prnewswire.com/news-releases/nuvasive-launches-magec-x-for-early-onset-scoliosis-treatment-300683395.html
SOURCE NuVasive, Inc.